The Children´s Hospital of Philadelphia
Welcome,         Profile    Billing    Logout  
 7 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Loomes, Kathleen
BOLD, NCT04336722 / 2019-003807-37: Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Active, not recruiting
3
254
Europe, Canada, US, RoW
Odevixibat, Placebo
Albireo, an Ipsen Company
Biliary Atresia
06/26
07/26
EMBARK, NCT04524390 / 2020-000974-22: Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

Completed
2
75
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625, Placebo
Mirum Pharmaceuticals, Inc.
Biliary Atresia
11/23
02/24
NCT04720456: SHAPE of Portal Hypertension in Children

Recruiting
2
120
US
SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles), SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Thomas Jefferson University, Children's Hospital of Philadelphia, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypertension, Portal
07/24
08/24
TRIUMPH, NCT04862221: TReatment for ImmUne Mediated PathopHysiology

Recruiting
2
163
US
High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
01/26
01/27
LEAP, NCT06193928: Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome

Recruiting
N/A
50
US
Maralixibat
Mirum Pharmaceuticals, Inc.
Alagille Syndrome
09/28
09/28
PROBE, NCT00061828: A Prospective Database of Infants With Cholestasis

Recruiting
N/A
1000
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Biliary Atresia, Neonatal Cholestasis
05/29
05/29
BASIC, NCT00345553: Biliary Atresia Study in Infants and Children

Recruiting
N/A
1265
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Biliary Atresia
05/29
05/29
LOGIC, NCT00571272: Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis

Suspended
N/A
1675
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency
05/29
05/29
MITOHEP, NCT01148550: Longitudinal Study of Mitochondrial Hepatopathies

Suspended
N/A
67
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
05/29
05/29
NCT04181138: Primary Sclerosing Cholangitis in Children

Recruiting
N/A
1000
Canada, US
Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
05/29
05/29
NCT05272319: Genetic Collection Protocol

Recruiting
N/A
2230
Canada, US
Arbor Research Collaborative for Health
Liver Diseases
05/29
05/29
Rogers, Michael
BOLD, NCT04336722 / 2019-003807-37: Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Active, not recruiting
3
254
Europe, Canada, US, RoW
Odevixibat, Placebo
Albireo, an Ipsen Company
Biliary Atresia
06/26
07/26

Download Options